Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

被引：0

作者：

Fisher, Benjamin A. ^{[1
]}

Mariette, Xavier ^{[2
]}

Papas, Athena S. ^{[3
]}

Grader-Beck, Thomas ^{[4
]}

Bootsma, Hendrika ^{[5
]}

Ng, Wan-Fai ^{[6
]}

Van Daele, Paul ^{[7
]}

Finzel, Stephanie ^{[8
]}

Elgueta, Sergio ^{[9
]}

Hermann, Josef ^{[10
]}

McCoy, Sara ^{[11
]}

Bookman, Arthur ^{[12
]}

Sopala, Monika ^{[13
]}

Luo, Wen-Lin ^{[14
]}

Scheurer, Cornelia ^{[13
]}

Hueber, Wolfgang ^{[13
]}

机构：

[1] Univ Birmingham, Birmingham, W Midlands, England

[2] Univ Paris Saclay, Le Kremlin Bicetre, France

[3] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA

[4] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA

[5] Univ Med Ctr Groningen, Dept Rheumatol, Groningen, Netherlands

[6] Newcastle Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, Tyne & Wear, England

[7] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[8] Univ Freiburg, Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany

[9] Clin Res Chile SpA, Biomed Res Ctr, Valdivia, Chile

[10] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria

[11] Univ Wisconsin, Sch Med & Publ Hlth, Middleton, WI USA

[12] Toronto Western Hosp, Toronto, ON, Canada

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1634

引用

页码：3242 / 3244

页数：3

共 50 条

[1] Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
Fisher, Benjamin A.
Mariette, Xavier
Papas, Athena
Grader-Beck, Thomas
Bootsma, Hendrika
Ng, Wan-Fai
van Daele, P. L. A.
Finzel, Stephanie
Noaiseh, Ghaith
Elgueta, Sergio
Hermann, Josef
McCoy, Sara S.
Akpek, Esen
Bookman, Arthur
Sopala, Monika
Montecchi-Palmer, Michela
Luo, Wen-Lin
Scheurer, Cornelia
Hueber, Wolfgang
LANCET, 2024, 404 (10452): : 540 - 553
[2] Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
Doerner, Thomas
Bowman, Simon J.
Fox, Robert
Mariette, Xavier
Papas, Athena
Grader-Beck, Thomas
Fisher, Benjamin A.
Barcelos, Filipe
De Vita, Salvatore
Schulze-Koops, Hendrik
Moots, Robert J.
Junge, Guido
Woznicki, Janice
Sopala, Monika
Avrameas, Alexandre
Luo, Wen-Lin
Hueber, Wolfgang
ARTHRITIS & RHEUMATOLOGY, 2025,
[3] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
Doerner, T.
Bowman, S. J.
Fox, R.
Mariette, X.
Papas, A.
Grader-Beck, T.
Fisher, B. A.
Barcelos, F.
De Vita, S.
Schulze-Koops, H.
Moots, R. J.
Junge, G.
Woznicki, J.
Sopala, M.
Luo, W.
Hueber, W.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 88
[4] Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Doerner, Thomas
Bowman, Simon J.
Fox, Robert
Mariette, Xavier
Papas, Athena
Grader-Beck, Thomas
Fisher, Ben A.
Barcelos, Filipe
De Vita, Salvatore
Schulze-Koops, Hendrik
Moots, Robert
Junge, Guido
Woznicki, Janice
Sopala, Monika
Luo, Wen-Lin
Hueber, Wolfgang
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2063 - 2065
[5] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Oakes, Tina Marie Myers
Skljarevski, Vladimir
Zhang, Qi
Kielbasa, William
Hodsdon, Michael E.
Detke, Holland C.
Camporeale, Angelo
Saper, Joel R.
CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
[6] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
Dorner, T.
Bowman, S. J.
Fox, R.
Mariette, X.
Papas, A.
Grader-Beck, T.
Fisher, B. A.
Barcelos, F.
De Vita, S.
Schulze-Koops, H.
Moots, R. J.
Junge, G.
Woznicki, J.
Sopala, M.
Luo, W. L.
Hueber, W.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 593 - 594
[7] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
Muir, A.
Goodman, Z.
Levy, C.
Janssen, H.
Montano-Loza, A.
Bowlus, C.
Ding, D.
Jia, C.
McColgan, B.
Myers, R.
Subramanian, M.
McHutchison, J.
Manns, M.
Chapman, R.
Afdhal, N.
Eksteen, B.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
[8] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
Dubourg, Julie
Ueki, Kohjiro
Grouin, Jean-Marie
Fouqueray, Pascale
DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
[9] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
Papp, K. A.
Menter, A.
Strober, B.
Langley, R. G.
Buonanno, M.
Wolk, R.
Gupta, P.
Krishnaswami, S.
Tan, H.
Harness, J. A.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 668 - 677
[10] Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
Pandya, Amit G.
Ezzedine, Khaled
Passeron, Thierry
van Geel, Nanja
Brown, Kurt
Santos, Leandro
Erskine, Lois
Wagya, Kofi
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191

← 1 2 3 4 5 →